September 10, 2014

Mylan announced that its subsidiary, Mylan Ireland Limited, has agreed to acquire the U.S. rights relating to Arixtra (fondaparinux sodium) injection and the authorized generic version of Arixtra from Aspen Global. 

September 5, 2014

Mylan on Friday announced that it has launched a generic version of Hoffmann-La Roche's Boniva injection.

August 24, 2014

IMS Health VP industry relations Doug Long briefed a packed house of NACDS TSE attendees on the latest trends shaping the U.S. pharmaceutical market.

August 24, 2014

IMS Health VP global supply services Hossam Sadek presented the IMS Health Bernie Greenberg Pharmacy Partnership Award to Walgreens group VP pharmaceutical development, Gerry Gleeson, during an Insight Session Sunday morning.

August 20, 2014

Pfizer successfully switched Nexium to over-the-counter in late May, and with that brought a $6 billion book of prescription business to antacid aisles, according to IMS Health data compiled over 2012.

July 10, 2014

As lifetime earnings for pharmaceuticals decrease, commercialization expenses increase and payers tighten their belts on reimbursement, life science companies will be faced with shrinking margins over the next few years. In order to maintain basic operating margin levels and continue investing in research and development at current levels, life science manufacturers will be forced to reduce costs by more than $35 billion by 2017, according to results from a new survey of 70 life science organizations from the IMS Institute for Healthcare Informatics.

June 24, 2014

As Walgreens carefully considers how to best execute the second step of its acquisition of Alliance Boots, Walgreens on Tuesday relayed its progress in improving its domestic business, including the company's success in winning the prescription business of high-value seniors and the pending national launch of its Boots No7 beauty brand.

May 15, 2014

The stampede of big-selling branded medicines that hurtled off the patent cliff in 2011 and 2012 has slowed to a relative trickle.

May 15, 2014

Call it the triumph of irrationality over self-interest. Healthcare experts and pharmacy leaders have been grappling with the challenge of patient nonadherence for decades.

May 7, 2014

The pace of annual global spending on oncology medicines — which is approaching the $100 billion threshold — has moderated over the past five years, even as a surge in innovative and targeted therapies has brought new therapeutic options to the growing number of patients being treated for cancer and as survival rates for most tumor types continue to increase, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics.

April 4, 2014

IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders.

March 25, 2014

Sales of specialty medicines are shifting toward hospitals and specialty pharmacies and away from independent physician owned-and-operated clinics, according to a report released Tuesday by HDMA's non-profit research foundation, The Center for Healthcare Supply Chain Research.

March 25, 2014

Walgreens on Tuesday posted a sales increase of 5.1% to $19.6 billion for the second quarter ended Feb. 28. First-half sales were up 5.5% to $37.9 billion.

March 24, 2014

IMS Health Holdings is expected to launch an initial public stock offering in two weeks, according to a report Sunday in the Wall Street Journal.

March 12, 2014

Three-in-four pharmaceutical companies are looking to derive greater value from the influx of healthcare information that includes anonymized electronic medical records and other real-world data, according to a report issued by the IMS Institute for Healthcare Informatics on Wednesday. New investments in a range of commercial operations applications — such as customer relationship management, social media or integrated multi-channel marketing solutions — were cited by more than 70% of respondents as a priority.

February 18, 2014

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

February 18, 2014

To put it in Facebook terms, the pharmaceutical industry by and large has yet to friend American consumers.

February 7, 2014

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity.
A recent paper from the Centers for Medicare and Medicaid Services delves into these issues and more.

January 21, 2014

With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report by the IMS Institute for Healthcare Informatics.

January 17, 2014

Par Pharmaceutical on Thursday announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin (digoxin) tablets.

January 7, 2014

Ani Pharmaceuticals has bought 31 generic drugs from Teva Pharmaceuticals for $12.5 million, the company said.

January 3, 2014

IMS Health is looking to go public, the healthcare industry research and analytics company said.

December 26, 2013

Earlier this year, the IMS Institute for Healthcare Informatics, the research wing of the healthcare industry analysis firm IMS Health, dropped a bombshell when it showed that U.S. spending on drugs fell in 2012, the first time that had happened in 55 years.

December 18, 2013

The U.S. healthcare system saved $217 billion in 2012 thanks to the use of generic drugs, according to a new report by a generic drug industry trade group.